Xiaowen specialises in M&A transactions and corporate law structuring of national and international companies. She has particular expertise in the area of corporate transactions and structuring in the healthcare sector, is familiar with the specifics of the highly regulated healthcare sector and has excellent networks there.
Of particular note are the approximately 60 M&A transactions for the creation of medical care centre groups as well as nine clinic transactions which underline her successful track record for ongoing advice to various corporate groups. On the product side, Xiaowen is also an experienced legal adviser with medtech, biotech and pharmaceutical transactions, including digital health investments. As a native Chinese speaker and member of the China Group, Xiaowen also advises Chinese companies and investors on outbound activities in Germany and Europe.
|Since 2017||Salary Partner, Taylor Wessing|
|2015 – 2017||Senior Associate, Taylor Wessing|
|2012 – 2015||Associate, Taylor Wessing|
|2012||Admitted as a lawyer, Hamburg|
|2010 – 2012||Preparing a dissertation in the field of European tax law, Europainstitut, University of Saarland|
|2009||Second state examination, Rheinland–Pfalz|
|2008||First state examination, Heidelberg|
|2007 – 2009||Legal clerkship, Rheinland–Pfalz|
|2002 – 2007||Legal studies, Ruprecht–Karls–University, Heidelberg|
|2004 – 2005||Overseas semester, Université Robert Schuman, Faculté de droit, de sciences politiques et de gestion, Strasbourg, France|
|2002||German–French Abitur/Baccalauréat (Deutsch–Französisches Gymnasium Saarbrücken)|
Kommentar „VC-Investments im Digital Health-Sektor“ / Health & Care Management 7–8/2019
Kommentar „Die Insolvenz eines privaten Klinikbetreibers – das Ende?“ / Health & Care Management 4/2019
Post-Merger Integration und Corporate Governance bei chinesischen Outbound–Investitionen in Deutschland – Erschienen in Yuanshi Bu (Hrsg.), Chinesische Outbound–Investitionen in Deutschland, 2014, p. 243 ff. (co-author)
Latest news & insights
Word on the street at the J.P. Morgan Healthcare Conference 2023
by multiple authors
Does a clinical trial render the pharmaceutical formulation used therein public?
Advising on Graig's sale of Idwal Marine Services to LDC
by multiple authors
AI software ChatGPT – actually a medical device?
Dr. Oliver Kirschner
Dr. Oliver Klöck
Karolina Lange-Kulmann, LL.M. (Medizinrecht)
Stephan Doom, Solicitor (England & Wales)|LL.M. (Nottingham)
Dr. Anne Steinhardt
Dr. Rembert T. Graf Kerssenbrock, LL.M. (Beijing)